Skip to navigation Skip to content
  • The Cancer Letter on Facebook
  • The Cancer Letter on Twitter
  • The Cancer Letter on LinkedIn

The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
  • SUBSCRIBE
  • Login
  • SUBSCRIBE
  • Login
The Cancer Letter
Home
  • About
    • Our Readers
    • Our History
    • Our Contributors
    • Contact Us
    • Store
  • Current Issue
    • Past Issues
  • Podcast
    • The Directors
  • Events
  • Job Board
Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
Conversation with The Cancer Letter

Letai: Perceptions aside, money is flowing and the cancer research infrastructure is sturdy
NCI expects record-breaking spending on extramural research

April 10, 2026
Vol.52 No.14
By Claire Marie Porter and Paul Goldberg
The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes
PodcastThe Directors

The Directors: Wistar’s Altieri and ChristianaCare’s Petrelli say partnership of their institutions will go on as the guard changes

March 27, 2026
Vol.52 No.12
By Sara Willa Ernst and Paul Goldberg
At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage
Podcast

At a jam-packed NCAB meeting, cancer vaccines and site visits take center stage

March 25, 2026
Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI

Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?”

March 20, 2026
Vol.52 No.11
By Claire Marie Porter
Letai: “From this point forward, it really is much more like business as usual at the NCI.”
NCI

Letai: “From this point forward, it really is much more like business as usual at the NCI.”

March 20, 2026
Vol.52 No.11
By Jacquelyn Cobb
Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition
In Brief

Kim Rathmell named OSUCCC director, Pollock becomes director emeritus in planned leadership transition

March 06, 2026
Vol.52 No.09
The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient
PodcastThe Directors

The Directors: Yolanda Sanchez and Kelvin Lee talk about making cancer centers more resilient
“Diverse ecosystems are more robust than non-diverse ecosystems. That is a biological fact.”

February 27, 2026
Vol.52 No.08
By Claire Marie Porter and Paul Goldberg
The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
NCI

The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.”

February 13, 2026
Vol.52 No.06
By Jacquelyn Cobb
Team USA’s Julie Letai competes in Milan Olympics speed skating event
In Brief

Team USA’s Julie Letai competes in Milan Olympics speed skating event

February 13, 2026
Vol.52 No.06
Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
NCI

Letai: NCAB’s ad hoc working group plays major role in advising NCI on extramural research
The group replaced the NCI Board of Scientific Advisors

February 06, 2026
Vol.52 No.05
By Claire Marie Porter

Posts navigation

Previous1234…40Next

Trending Stories

  • Is it time to re-assess the practice and practicality of screening colonoscopy?
    Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives
  • The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
    Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
  • FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
    Clinical benefit will not be considered for approval, FDA says
  • Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
  • From “default dead” to living the future of cancer care
    As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
  • The Galleri MCD vote: What FDA asked its advisors to ignore

ABOUT
ABOUT
About The Cancer Letter
Accessibility Statement
Our Contributors
Editorial policies
Store
SUBSCRIPTIONS
SUBSCRIPTIONS
Our readers
Pricing
News alerts
About IP login
Job board
CONTACT
CONTACT
Contact us
Submission guidelines
Advertise
Careers
SEE ALSO
Cancer History Project
The Cancer Letter
Copyright © 2026 The Cancer Letter Inc. All rights reserved.
Privacy Policy
Terms & Conditions
FOLLOW US
Instagram
Twitter
LinkedIn
Facebook
Vimeo
Scroll to top
Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.
SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.
LOGINSUBSCRIBE NOW
SEARCH DATE
SEARCH TEXT
      Cancel
      OK
      Cancel
      OK
      Delete Account
      Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below
      No

      Never miss an issue!

      Get alerts for our award-winning coverage in your inbox.

      Login

       
      Forgot Password?

      Site license subscribers:
      Log in with your IP | Register a sponsored account